newsfilter
← Latest News
GlobeNewswire·

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

  • Zevra Therapeutics, Inc. announced that its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET.
  • Management will hold one-on-one meetings with registered conference attendees.
  • A live webcast of the presentation will be available on the "Events & Presentations" page of Zevra's investor relations website at investors.zevra.com.
  • Zevra is a commercial-stage company focused on rare diseases, with its lead product marketed in the U.S. for Niemann-Pick disease type C.
  • The Company's strategy includes geographic expansion, advancing its pipeline toward key milestones, & delivering meaningful therapeutics.
  • Forward-looking statements in the release are subject to risks detailed in Zevra's 2025 Form 10-K filed March 9, 2026, & its 2026 Form 10-Q filed May 6, 2026.
  • Investor inquiries can be directed to Nichol Ochsner at +1 (732) 754-2545 or noonchner@zevra.com.
  • Media inquiries can be directed to Julie Downs at +1 (508) 246-3230 or jdowns@zevra.com.